OCS
Oculis Holding AG
$11.45
-1.38%
$663.9M
No data for this timeframe.
Vol
Market Cap$663.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
SEC Reports2
Press Releases8
Recent Activity
Jun 11, 2026
Press
Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid small
Impact 3/10
Jun 11, 2026
fda
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
<p align="justify">ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq:
Jun 9, 2026
Press
Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial for Licaminlimab in dr
Impact 5/10
May 11, 2026
SEC
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi
PRESS-RELEASE — Impact 5/10
May 11, 2026
SEC
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s
PRESS-RELEASE — Impact 5/10
Price Targets
$38.30
+234.5% upside
Strong Buy
Current $11.45
Low $22.85
Median $39.51
High $52.39
11 analysts
$22.85
$52.39
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Jun 1, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Jun 1, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| Jun 1, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.39 ▲ +11.0% | $-0.45 — $-0.26 | 21% YoY | 9 |
| Next Q | $-0.41 ▲ +9.9% | $-0.50 — $-0.30 | -28% YoY | 9 |
| Current FY | $-1.77 ▼ -1.2% | $-1.97 — $-1.58 | 6% YoY | 9 |
| Next FY | $-1.64 ▲ +2.9% | $-2.21 — $-1.21 | 7% YoY | 8 |
Latest Reports
NEUTRAL
Press
3/10
Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid small
Jun 11, 2026
NEUTRAL
PRESS-RELEASE
5/10
Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi
May 11, 2026
NEUTRAL
PRESS-RELEASE
5/10
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s
May 11, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.0/10.
NEUTRAL
3/10
Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privoseg
Jun 11, 2026
NEUTRAL
5/10
Oculis announced the first patient randomized in PREDICT-1, a genotype-based registrational trial fo
Jun 9, 2026
BEARISH
7/10
Oculis announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 in diabetic macular edem
May 29, 2026
BULLISH
7/10
Oculis announced FDA Special Protocol Assessment (SPA) agreement for the PIONEER-1 Phase 3 trial of
May 7, 2026
NEUTRAL
5/10
Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasiv
May 5, 2026
MIXED
6/10
Oculis announced completion of the final patient visit in its Phase 3 DIAMOND program for OCS-01, a
Apr 20, 2026
BULLISH
8/10
Oculis Holding AG announced positive Phase 2 ACUITY trial results for its investigational neuroprote
Mar 16, 2026
MIXED
7/10
Oculis reported its 2025 financial results and clinical progress, highlighting a strong cash positio
Mar 3, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$38.30 mean target
+234.5% upside
Strong Buy (1.27)
$22.85 Low
$52.39 High
| Metric | Value |
|---|---|
| Current Price | $11.45 |
| Target Low | $22.85 |
| Target Mean | $38.30 |
| Target Median | $39.51 |
| Target High | $52.39 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.27) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.39 | $-0.45 | $-0.26 | 21.1% | +11.0% | 6↑ 1↓ | $0.0B | -34.8% | 9 |
| Next Q 2026-09-30 |
$-0.41 | $-0.50 | $-0.30 | -28.4% | +9.9% | 5↑ 2↓ | $0.0B | -29.8% | 9 |
| Current FY 2026-12-31 |
$-1.77 | $-1.97 | $-1.58 | 6.5% | -1.2% | 3↑ 5↓ | $0.0B | -31.4% | 9 |
| Next FY 2027-12-31 |
$-1.64 | $-2.21 | $-1.21 | 7.5% | +2.9% | 5↑ 2↓ | $0.0B | 862.9% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.387 | |
| 7d ago | $-0.387 | |
| 30d ago | $-0.434 | +0.048 |
| 60d ago | $-0.434 | +0.048 |
| 90d ago | $-0.434 | +0.048 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jun 2, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Jun 1, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | Needham | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 21, 2026 | Guggenheim | INITIATE | — | Buy |
| May 18, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 5, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | JP Morgan | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
fda
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
<p align="justify">ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a glo
Jun 11, 2026
other
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
<p align="justify"><b>ZUG, Switzerland, June 11, 2026</b> – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharma
Jun 10, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to
Jun 9, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Compa
Jun 9, 2026
other
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
<p align="justify">ZUG, Switzerland, June 9, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focuse
Jun 9, 2026
fda
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
<p align="justify">ZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceu
Jun 8, 2026
other
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
<p align="justify">ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a glo
Jun 8, 2026
other
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
<p align="justify">Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations a
Jun 8, 2026
short_volume
Short Volume: OCS — 72.6% short (0.4M / 0.6M)
Short: 418,839 | Exempt: 94 | TRF Vol: 576,886 | Short Ratio: 72.6% | Off-exchange volume (dark pool + OTC)
May 29, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to
May 29, 2026
fda
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
<p align="justify">ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutic
May 29, 2026
routine
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
<p>ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- </p> <p align="center"><i>Conference call today at 4:30 pm ET </i></p>
May 28, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, May 28, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to
May 15, 2026
other
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
<p>ZUG, Switzerland, May 15, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to
May 14, 2026
earnings
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
<p align="justify">ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today